a-semi-automated-reproducible-biological-based-method-to-quantify

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition <em>In Vitro</em>

Vascular calcification involves a series of degenerative pathologies, including inflammation, changes to cellular phenotype, cell death, and the absence ...

RWTH Aachen University

Vascular calcification is an active process that increases cardiovascular disease (CVD) risk. There is still no consensus on an appropriate biomarker for vascular calcification. We reasoned that the biomarker for vascular calcification is the collection of all blood components that can be sensed and integrated into a calcification response by human vascular smooth muscle cells (hVSMCs).

Development of the BioHybrid Assay: Combining Primary Human Vascular Smooth Muscle Cells and Blood to Measure Vascular Calcification Propensity.

Vascular calcification is a prominent feature of late-stage diabetes, renal and cardiovascular disease (CVD), and has been linked to adverse events. Recent studies in patients reported that plasma levels of osteomodulin (OMD), a proteoglycan involved in bone mineralisation, associate with diabetes and CVD. We hypothesised that OMD could be implicated in these diseases via vascular calcification as a common underlying factor and aimed to investigate its role in this context.

Robert Dzhanaev

Helmholtz Institute for Biomedical Engineering,
Biointerface Group,
Helmholtz Institute for Biomedical Engineering, Biointerface Group

RWTH Aachen University

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Robert Dzhanaev

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Helmholtz Institute for Biomedical Engineering,Biointerface Group,Helmholtz Institute for Biomedical Engineering, Biointerface Group

RWTH Aachen University

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Helmholtz Institute for Biomedical Engineering,
Biointerface Group,
Helmholtz Institute for Biomedical Engineering, Biointerface Group